#Taipei #USA #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Progresses with AJ201 for SBMA

AnnJi Pharmaceutical Co., Ltd. has announced its significant advancement in drug development by initiating the pivotal Phase 3 trial for its promising therapy, AJ201 (rosolutamida), aimed at treating Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease. This announcement comes on the heels of the FDA's acceptance of the company's protocol, allowing it to move ahead with activating clinical trial centers across the United States.

A Historical Context for AJ201

AJ201 is a groundbreaking oral small molecule that has been meticulously designed to address multiple pathological mechanisms associated with SBMA. As an ultra-rare, hereditary neuromuscular disorder, SBMA can lead to severe muscle atrophy and progressive loss of motor function, significantly impacting the quality of life of those affected and their families. It is particularly notable that this phase of the study is the only ongoing clinical trial worldwide specifically targeting SBMA at such a scale.

The trajectory of AJ201 is impressive, having earned the rare designation and fast-track status from the FDA, as well as orphan medicinal product designation in both the United States and the European Union. These accolades signify a crucial recognition of the unmet medical need in treating SBMA, where no therapies are currently approved.

Understanding the Mechanism of Action

The clinical efficacy of AJ201 lies in its ability to eliminate the pathogenic mutant androgen receptor (mAR) protein while also activating various cellular stress response pathways, including Nrf1, Nrf2, and HSF1. This multifaceted approach positions AJ201 as a pioneering treatment capable of modifying the disease progression of SBMA.

The encouraging results observed in the completed Phase 2 trial of AJ201, released in May 2025, have laid a robust foundational platform for the Phase 3 study. Moving forward, the ROMA-KD trial will adopt a global, multicenter, randomized, double-blind and placebo-controlled study design. The research will involve approximately 200 symptomatic SBMA patients globally, with a strategic focus on patient recruitment in the U.S.

Advisory Board: Voices from the Community

AnnJi Pharmaceutical has also initiated a Patient and Caregiver Advisory Board dedicated to SBMA, first introduced at the 2026 International Scientific and Patient Conference hosted by the Kennedy’s Disease Association (KDA). This represents an intrinsic commitment to integrating patient experiences and insights into the development process. The council provides a platform for continuous dialogue between AnnJi and the SBMA community, ensuring that the perspectives shared can directly influence clinical strategy and materials directed at patients.

Dr. Wendy Huang, CEO and Chairwoman of AnnJi, expressed the importance of this initiative in addressing the real-world challenges faced by those living with SBMA: “For individuals coping with SBMA, even the simplest of tasks can become monumental challenges. Our progress with AJ201 into Phase 3 is not just about drug development, but signifies hope towards changing the lives of families affected by this condition.”

A Commitment to Innovation and Collaboration

AnnJi remains devoted to advancing therapeutic strategies for the SBMA community, emphasizing transparent collaboration with patients, healthcare professionals, and patient advocacy organizations across the globe.

A Glimpse into Future Expectations

The scale of the ongoing Phase 3 trial could potentially herald significant advancements in the fight against SBMA. As this trial begins, the hope remains that AJ201 will pave the way for a revolutionary treatment modality, not merely to manage symptoms, but to fundamentally modify disease progression, ultimately improving the lives of those who suffer from this debilitating condition.

AJ201 represents more than just a clinical candidate; it embodies the collective aspirations of patients, families, and partners striving for breakthroughs in the face of intriguing yet daunting challenges posed by rare diseases.

AnnJi's journey thus continues not only in the realm of science but also within the hearts and minds of those who dare to hope for a brighter future in the battle against neurological diseases.